Incidence in the Contrast induce nephropathy with CTO PCI in Diabetic patients

Abstract

Background: The incidence of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) with chronic total occlusion (CTO) in diabetic patients is not well established. The purpose of this study was to determine the incidence of CIN after CTO PCI in diabetic patients.

Methodology: The study conducted in department of cardiology HMC Peshawar from Jan 2019 to Jan 2023 in this retrospective study involving 818 patients who underwent CTO PCI at a single center. Data were collected from medical records. The primary outcome was the incidence of CIN. Secondary outcomes included major adverse cardiac events (MACE) and mortality. Multivariate logistic regression was used to assess the association between diabetes and CIN.

Results: A total of 818 patients were included in this study. Of these, 616 (75.4%) were male and 202 (24.6%) were female. The mean age of the patients was 62.5 ± 11.1 years. The prevalence of diabetes was 49.6%. The overall incidence of CIN was 5.9%. The incidence of CIN was significantly higher in diabetic patients (10.2%) than in non-diabetic patients (2.9%; p <0.001). The incidence of MACE at 30 days was significantly higher in diabetic patients than in non-diabetic patients (7.0% vs. 4.2%; p = 0.022). The 30-day mortality rate was also significantly higher in diabetic patients than in non-diabetic patients (3.9% vs. 1.2%; p = 0.002).

Conclusion: The incidence of CIN after CTO PCI is significantly higher in diabetic patients compared to non-diabetic patients. Appropriate preventive measures should be taken to reduce the risk of CIN in this population.